Clinicians' Views of Hepatitis C Virus Treatment Candidacy With Direct-Acting Antiviral Regimens for People Who Inject Drugs

Substance Use and Misuse

Volumn 51, Issue 9, 2016, Pages 1218-1223

  Asher, Alice K ^a   Portillo, Carmen J ^a   Cooper, Bruce A ^a   Dawson Rose, Carol ^a   Vlahov, David ^a   Page, Kimberly A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

abstinence; direct acting antiviral hepatitis treatment candidacy; hepatitis C cure; Hepatitis C treatment; injection drug use; people who inject drugs (PWID); providers

Indexed keywords

ANTIVIRUS AGENT;

HEPACIVIRUS; HEPATITIS C; HUMAN; SUBSTANCE ABUSE;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84969850578     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.3109/10826084.2016.1161054     Document Type: Article

References (23)

1. A.Aghemo,, & R.De Francesco, (2013). New horizons in Hepatitis C antiviral therapy with direct-acting antivirals. Hepatology, 58, 428–438.
2. A.Asher,, P.J.Lum,, & K.Page, (2012). Assessing candidacy for acute hepatitis C treatment among active young injection drug users: A case-series report. Journal of the Association of Nurses in AIDS Care, 23(1), 16–29.
3. M.Backmund,, K.Meyer,, & B.R.Edlin, (2004). Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clinical Infectious Diseases, 39(10), 1540–1543.
4. A.W.Batchelder,, D.Peyser,, S.Nahvi,, J.H.Arnsten,, & A.H.Litwin, (2015). “Hepatitis C treatment turned me around:” Psychological and behavioral transformation related to hepatitis C treatment. Drug & Alcohol Dependence, 153, 66–71.
5. B.Efron, (2000). The bootstrap and modern statistics. Journal of the American Statistical Association, 95(452), 1293–1296.
6. D.M.Erceg-Hurn,, & V.M.Mirosevich, (2008). Modern robust statistical methods: An easy way to maximize the accuracy and power of your research. American Psychologist, 63(7), 591–601.
7. M.G.Ghany, (2015). The ongoing debate of who to treat for chronic hepatitis C virus. JAMA Internal Medicine, 175(2), 169–170.
8. B.P.Grady,, J.W.Vanhommerig,, J.Schinkel,, C.J.Weegink,, S.M.Bruisten,, C.E.Lindenburg,, & Prins, M. (2012). Low incidence of reinfection with the hepatitis C virus following treatment in active drug users in Amsterdam. European Journal of Gastroenterology & Hepatology, 24(11), 1302–1307.
9. J.Grebely,, E.Knight,, T.Ngai,, K.A.Genoway,, J.D.Raffa,, M.Storms,, … Conway, B. (2010). Reinfection with hepatitis C virus following sustained virological response in injection drug users. Journal of Gastroenterology and Hepatology, 25(7), 1281–1284.
10. L.M.Hagan,, & R.F.Schinazi, (2013). Best strategies for global HCV eradication. Liver International, 33(Suppl 1), 68–79.
11. L.M.Hagan,, P.R.Wolpe,, & R.F.Schinazi, (2013). Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends in Microbiology, 21(12), 625–633.
12. M.Hellard,, J.S.Doyle,, R.Sacks-Davis,, A.J.Thompson,, & E.McBryde, (2014). Eradication of hepatitis C infection: The importance of targeting people who inject drugs. Hepatology, 59(2), 366–369.
13. M.Hellard,, R.Sacks-Davis,, & J.Gold, (2009). Hepatitis C treatment for injection drug users: A review of the available evidence. Clinical Infectious Diseases, 49(4), 561–573.
14. K.V.Kowdley,, E.Lawitz,, I.Crespo,, T.Hassanein,, M.N.Davis,, M.DeMicco,, … Jacobson, I. M. (2013). Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomised, multicentre phase 2 trial. Lancet, 381(9883), 2100–2107.
15. E.Lawitz,, A.Mangia,, D.Wyles,, M.Rodriguez-Torres,, T.Hassanein,, S.C.Gordon,, … Gane, E. J. (2013). Sofosbuvir for previously untreated chronic hepatitis C infection. New England Journal of Medicine, 368(20), 1878–1887.
16. S.H.Mehta,, B.L.Genberg,, J.Astemborski,, R.Kavasery,, G.D.Kirk,, D.Vlahov,, … Thomas, D. L. (2008). Limited uptake of hepatitis C treatment among injection drug users. Journal of Community Health, 33(3), 126–133.
17. J.A.Morrill,, M.Shrestha,, & R.W.Grant, (2005). Barriers to the treatment of hepatitis C. Patient, provider, and system factors. Journal of General Internal Medicine, 20(8), 754–758.
18. A.Myles,, G.J.Mugford,, J.Zhao,, M.Krahn,, & P.P.Wang, (2011). Physicians' attitudes and practice toward treating injection drug users with hepatitis C: Results from a national specialist survey in Canada. Canadian Journal of Gastroenterology, 25(3), 135–139.
19. Primrose Healthcare. (2015, July 8). The burden of hepatitis C virus disease in commercial and managed Medicaid populations. Retrieved from http://www.milliman.com/uploadedFiles/insight/2015/milliman-hcv-burden.pdf
20. StataCorp. (2013). Stata statistical software: Release 13. College Station, TX: Author.
21. S.A.Strathdee,, M.Latka,, J.Campbell,, P.T.O'Driscoll,, E.T.Golub,, F.Kapadia,, … Study to Reduce Intravenous Exposures Project. (2005). Factors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users. Clinical Infectious Diseases, 40(Suppl 5), S304–S312.
22. Substance Abuse and Mental Health Services Administration. (2014). Results from the 2013 National Survey on Drug Use and Health: Summary of National Findings. Rockville, MD: Author.
23. R.Wehrens,, H.Putter,, & L.M.C.Buydens, (2000). The bootstrap: A tutorial. Chemometrics and Intelligent Laboratory Systems, 54(1), 35–52.